Cogdell Spencer (Charlotte, North Carolina) reported the recent completion of the 52,800 square foot rehabilitation hospital in Lancaster, Pennsylvania. This facility is owned by Cogdell Spencer Inc. and leased to an operating joint venture composed of St. Louis-based Centerre Healthcare and Lancaster General Hospital.

This facility, located on the Lancaster General Health Campus includes a therapeutic pool, gymnasium, 50 private rooms and space for intensive inpatient physical rehabilitation following strokes, trauma or other health care problems that result in severe disabilities.

“We are pleased with the completion of this first project in the Central Pennsylvania market,” said Andrew Woolley, Development Project Manager with Cogdell Spencer. “Lancaster General Hospital is a great client for Cogdell Spencer and we look forward to a long relationship in the community.”

Charlotte-based Cogdell Spencer is a real estate investment trust that invests in specialty office buildings for the medical profession, including medical offices, ambulatory surgery and diagnostic centers.

MFIC opens R&D center

MFIC (Newton, Massachusetts) reported the opening of the Microfluidics Technology Center, an R&D facility at MFIC’s headquarters in Newton.

MFIC bills itself as an industry-leader in fluid formulation processing equipment to produce small, liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

“The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics’ technology and pursuing groundbreaking work in the field of nanotechnology,” said Dr. Thomai Panagiotou, VP of Research and Development. He said the center will be “an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers—including potentially life-saving drugs—that to date could not be formulated.”

The Microfluidics Technology Center will provide customers full access to the company’s R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving their existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer materials processors.

MFIC, through its Microfluidics Division, manufactures Microfluidizer materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries.

Sagemark centers accredited

The Sagemark Companies (New York) reported that all of its imaging centers have received accreditation by the American College of Radiology (Reston, Virginia).

“We are delighted that each of our imaging centers has met the strict standards of the American College of Radiology,” said Michael Fagien, MD, chief medical officer for The Sagemark Companies.

“Our imaging facilities are centers of medical excellence and 100% ACR accreditation is a testament to the excellent imaging service we provide to each and every patient,” continued Dr. Fagien. “We are especially proud of the ACR accreditation on May 29th of Premier PET Imaging of Jacksonville for oncology and brain procedures, as well as for cardiac PET perfusion studies using ammonia N-13, to our knowledge, the only out-patient center in the United States to receive such an honor.”

Sagemark is a national owner and operator of out-patient PET and PET/CT medical diagnostic imaging centers.

Delcath in NASDAQ compliance

Delcath Systems (Stamford, Connecticut) has received notice from the NASDAQ that following the recent addition of Laura Philips, PhD, MBA and Jonathan Lewis, MD, PhD, to the company’s board of directors, Delcath is now in compliance with NASDAQ’s Marketplace Rule 4350, which requires its board to have a majority of independent directors and requires its audit committee to have three members. Delcath also received a letter from the Boston Stock Exchange informing the company that it is now in compliance with the BSE requirements concerning independent directors.